A digoxin derivative that potently reduces intraocular pressure: efficacy and mechanism of action in different animal models

Am J Physiol Cell Physiol. 2024 May 1;326(5):C1505-C1519. doi: 10.1152/ajpcell.00617.2023. Epub 2024 Apr 1.

Abstract

Glaucoma is a blinding disease. Reduction of intraocular pressure (IOP) is the mainstay of treatment, but current drugs show side effects or become progressively ineffective, highlighting the need for novel compounds. We have synthesized a family of perhydro-1,4-oxazepine derivatives of digoxin, the selective inhibitor of Na,K-ATPase. The cyclobutyl derivative (DcB) displays strong selectivity for the human α2 isoform and potently reduces IOP in rabbits. These observations appeared consistent with a hypothesis that in ciliary epithelium DcB inhibits the α2 isoform of Na,K-ATPase, which is expressed strongly in nonpigmented cells, reducing aqueous humor (AH) inflow. This paper extends assessment of efficacy and mechanism of action of DcB using an ocular hypertensive nonhuman primate model (OHT-NHP) (Macaca fascicularis). In OHT-NHP, DcB potently lowers IOP, in both acute (24 h) and extended (7-10 days) settings, accompanied by increased aqueous humor flow rate (AFR). By contrast, ocular normotensive animals (ONT-NHP) are poorly responsive to DcB, if at all. The mechanism of action of DcB has been analyzed using isolated porcine ciliary epithelium and perfused enucleated eyes to study AH inflow and AH outflow facility, respectively. 1) DcB significantly stimulates AH inflow although prior addition of 8-Br-cAMP, which raises AH inflow, precludes additional effects of DcB. 2) DcB significantly increases AH outflow facility via the trabecular meshwork (TM). Taken together, the data indicate that the original hypothesis on the mechanism of action must be revised. In the OHT-NHP, and presumably other species, DcB lowers IOP by increasing AH outflow facility rather than by decreasing AH inflow.NEW & NOTEWORTHY When applied topically, a cyclobutyl derivative of digoxin (DcB) potently reduces intraocular pressure in an ocular hypertensive nonhuman primate model (Macaca fascicularis), associated with increased aqueous humor (AH) flow rate (AFR). The mechanism of action of DcB involves increased AH outflow facility as detected in enucleated perfused porcine eyes and, in parallel, increased (AH) inflow as detected in isolated porcine ciliary epithelium. DcB might have potential as a drug for the treatment of open-angle human glaucoma.

Keywords: Na,K-ATPase; digoxin derivative; intraocular pressure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aqueous Humor* / drug effects
  • Aqueous Humor* / metabolism
  • Ciliary Body / drug effects
  • Ciliary Body / metabolism
  • Digoxin* / pharmacology
  • Disease Models, Animal
  • Glaucoma / drug therapy
  • Glaucoma / metabolism
  • Glaucoma / physiopathology
  • Humans
  • Intraocular Pressure* / drug effects
  • Macaca fascicularis*
  • Male
  • Ocular Hypertension* / drug therapy
  • Ocular Hypertension* / metabolism
  • Ocular Hypertension* / physiopathology
  • Rabbits
  • Sodium-Potassium-Exchanging ATPase / antagonists & inhibitors
  • Sodium-Potassium-Exchanging ATPase / metabolism
  • Trabecular Meshwork / drug effects
  • Trabecular Meshwork / metabolism

Substances

  • Digoxin
  • Sodium-Potassium-Exchanging ATPase